首页>投融资
OMass Therapeutics
B轮
OMass Therapeutics, formerly known as OMass Technologies and a spin out of of University of Oxford, is a biotechnology company focused on developing small molecule compounds, using its OdyssION technology platform, for the potential treatment of rare diseases and immunological diseases.In April 2022, the company announced an USD 100 million Series B financing round led by GV, Northpond Ventures, Sanofi Ventures, Syncona, Oxford Science Enterprises and Oxford University.In February 2020, the company completed an extended series A financing of GBP 27.5 million (US$35.872) from existing investors Syncona Ltd and Oxford Sciences Innovation (OSI) who joined in the round with GBP 0.5 (US$0.652) million from the University of Oxford and contributed GBP16.6 (US$21.654) million and GBP10.4 (US$13.566) million respectively, that came after an initial Series A investment of GBP 14 (US$18.262) million in 2018 bringing the total series A to GBP 41.5 (US$54.135) million.In November 2018, the company
基本信息
-
公司全称OMass Therapeutics
-
类型罕见疾病、免疫疾病药物研发商
-
产业领域药品研发/制造、生物药
-
公司人数15~50人
-
地址John Smith Drive,ARC Oxford Bldg 4000,Chancellor Court OXFORD OXFORDSHIRE OX4; GB; Telephone: +4401865548350;
-
联系电话44 (0) 1865 548
-
邮箱info@omass.com
-
成立时间2016-01-01
投融资
-
2023-05-15B轮1000万英镑Sanofi VenturesBritish Patient CapitalOxford Science EnterprisesGVNorthpond VenturesSyncona Partners
-
2023-05-15B轮1000万英镑GVSynconaBritish Patient CapitalOxford Science Enterprises赛诺菲Northpond Ventures
-
2022-04-28B轮1亿美元GVSynconaUniversity of OxfordOxford Science Enterprises赛诺菲Northpond Ventures
-
2020-02-17A轮2750万英镑Syncona PartnersOxford Sciences Innovation
-
2020-02-17A轮2750万英镑Oxford Sciences InnovationSyncona
-
2018-11-21A轮1400万英镑Syncona Partners
-
2018-11-21A轮1400万英镑Syncona
-
2016-06-14未透露100万英镑Oxford Sciences Innovation
- 加载更多
相关投融资企业
捐赠/众筹/授予
igaTx 是一家生物技术公司，开发工程化单体 IgA 中性粒细胞接合器，以释放中性粒细胞对癌症的肿瘤杀伤能力，以及针对传染病的工程化二聚体 IgA 杀伤能力。该公司在工程治疗性 IgA 方面的前沿方法基于 Jeanette Leusen 教授在乌得勒支医学中心（荷兰乌得勒支）进行的开创性工作，并广泛适用于许多不同疾病。
C轮
SiteOne Therapeutics, founded by Stanford University, is a biotechnology company focused on the development of long-acting analgesics, non-norcotic analgecis and diagnostic imaging agents for pain and cancer.In May 2023, SiteOne Therapeutics Inc received a grant for up to $15 million from the National Institute on Drug Abuse.In January 2017, the company raised $15 million in a series B round of financing
A轮
PsiOxus Therapeutics Ltd was formed from the merger of Myotec Therapeutics and Hybrid BioSystems in December 2010. The company is focused on the development of novel therapeutics that address cancer and other clinically unmet diseases.Myotec Therapeutics was a spin-out from Imperial Innovations and was set up to develop technology originated at Imperial College London. It focused on repurposing drugs for the treatment of cachexia, with the intention of out-licensing after completion of phase II studies.In June 2017, the company expanded its operations into a 21,000 sq ft state-of-the-art facility on the Abingdon Science Park in Oxfordshire, UK and a new US facility in Plymouth Meeting near Philadelphia, PA.In April 2012, PsiOxus announced that it would expand into new facilities at the Milton Park in Oxfordshire, UK. The expansion would include a bespoke laboratory for the research and development of novel viral therapeutics; later that month, the facility was opened.By Decem
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息